Druker BJ - Search Results

1

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Danhauser-Riedl S, et al. Among authors: druker bj. Cancer Res. 1996 Aug 1;56(15):3589-96. Cancer Res. 1996. PMID: 8758931

2

Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Hallek M, Neumann C, Schäffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B. Hallek M, et al. Among authors: druker bj. Exp Hematol. 1997 Dec;25(13):1367-77. Exp Hematol. 1997. PMID: 9406996

3

CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.

Wendtner CM, Schmitt B, Gruss HJ, Druker BJ, Emmerich B, Goodwin RG, Hallek M. Wendtner CM, et al. Among authors: druker bj. Cancer Res. 1995 Sep 15;55(18):4157-61. Cancer Res. 1995. PMID: 7545087

4

Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase.

Okuda K, Sanghera JS, Pelech SL, Kanakura Y, Hallek M, Griffin JD, Druker BJ. Okuda K, et al. Among authors: druker bj. Blood. 1992 Jun 1;79(11):2880-7. Blood. 1992. PMID: 1375118 Free article.

5

BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells.

Neumann M, Wilisch A, Ma BC, Druker BJ, Serfling E, Franza BR Jr. Neumann M, et al. Among authors: druker bj. Anticancer Res. 1996 May-Jun;16(3A):1075-83. Anticancer Res. 1996. PMID: 8702216

6

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. Buchdunger E, et al. Among authors: druker bj. Cancer Res. 1996 Jan 1;56(1):100-4. Cancer Res. 1996. PMID: 8548747

7

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Hochhaus A, et al. Among authors: druker bj. Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741. Leukemia. 2002. PMID: 12399961 Clinical Trial.

8

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. Al-Ali HK, et al. Among authors: druker bj. Hematol J. 2004;5(1):55-60. doi: 10.1038/sj.thj.6200319. Hematol J. 2004. PMID: 14745431

9

Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.

Carlesso N, Griffin JD, Druker BJ. Carlesso N, et al. Among authors: druker bj. Oncogene. 1994 Jan;9(1):149-56. Oncogene. 1994. PMID: 8302574

10

The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.

Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ. Oda T, et al. Among authors: druker bj. Leukemia. 1995 Feb;9(2):295-301. Leukemia. 1995. PMID: 7869767

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

441 results

Search Page

Filters